Article
DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Journal of experimental & clinical cancer research : CR - 25 Sept 2012
Zhu Jian, Wang Yuyan, Duan Jianchun, Bai Hua, Wang Zhijie, Wei Lai, Zhao Jun, Zhuo Minglei, Wang Shuhang, Yang Lu, An Tongtong, Wu Meina, Wang Jie
Abstract excerpt
BACKGROUND: It is well known that genetic alternation of epidermal growth factor receptor (EGFR) plays critical roles in tumorgenesis of lung cancer and can predict outcome of non-small-cell lung cancer treatment, especially the EGFR tyrosine-kinase inhibitors (EGFR-TKIs) therapy. However, it is unclear whether epigenetic changes such as DNA methylation involve in the response to the EGFR-TKI therapy. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.